EUVIMEDEUVIMED entdecken
Crossref

Persistent Clinical Response of Infliximab Therapy in Patients with Refractory Rheumatoid Arthritis, over a 3-Year Period

Paraskevi V Voulgari, Yannis Alamanos, Alexandros A Drosos

Current Clinical Pharmacology · 2006

DOI: 10.2174/157488406775268264 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Clinical Pharmacology, 2006. Verfasst von Paraskevi V Voulgari und 2 weiteren Autor:innen. Beteiligte Einrichtung: Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece. Die Arbeit wurde bisher 2-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalArthritis, RheumatoidCyclosporineDrug Therapy, CombinationHumansInfliximabMagnetic Resonance ImagingMethotrexateTumor Necrosis Factor-alpha

Substanzen

Antibodies, MonoclonalTumor Necrosis Factor-alphaCyclosporineInfliximabMethotrexate

Autor:innen und Institutionen

  • Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece.

Zitieren

APA

Voulgari, P. V., Alamanos, Y., & Drosos, A. A. (2006). Persistent Clinical Response of Infliximab Therapy in Patients with Refractory Rheumatoid Arthritis, over a 3-Year Period. Current Clinical Pharmacology. https://doi.org/10.2174/157488406775268264

Vancouver

Voulgari PV, Alamanos Y, Drosos AA. Persistent Clinical Response of Infliximab Therapy in Patients with Refractory Rheumatoid Arthritis, over a 3-Year Period. Current Clinical Pharmacology. 2006. doi:10.2174/157488406775268264

BibTeX
@article{Voulgari2006,
  author = {Voulgari, Paraskevi V and Alamanos, Yannis and Drosos, Alexandros A},
  title = {Persistent Clinical Response of Infliximab Therapy in Patients with Refractory Rheumatoid Arthritis, over a 3-Year Period},
  journal = {Current Clinical Pharmacology},
  year = {2006},
  doi = {10.2174/157488406775268264}
}
Kostenlos starten →